Anne-Sophie Beignon

List of Publications by Year
in descending order

33	2,261	304743	377865
papers	citations	22 h-index	34 g-index

35	35	35	3279
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Optimize Prime/Boost Vaccine Strategies: Trained Immunity as a New Player in the Game. Frontiers in Immunology, 2021, 12, 612747.	4.8	62
2	Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response. Frontiers in Immunology, 2021, 12, 645210.	4.8	38
3	Predictive Markers of Immunogenicity and Efficacy for Human Vaccines. Vaccines, 2021, 9, 579.	4.4	25
4	The Route of Vaccine Administration Determines Whether Blood Neutrophils Undergo Long-Term Phenotypic Modifications. Frontiers in Immunology, 2021, 12, 784813.	4.8	3
5	Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations. Npj Vaccines, 2020, 5, 24.	6.0	24
6	Mass Cytometry Analysis Reveals Complex Cell-State Modifications of Blood Myeloid Cells During HIV Infection. Frontiers in Immunology, 2019, 10, 2677.	4.8	16
7	NK cell immune responses differ after prime and boost vaccination. Journal of Leukocyte Biology, 2019, 105, 1055-1073.	3.3	20
8	Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response. Scientific Reports, 2018, 8, 3087.	3.3	35
9	A computational approach for phenotypic comparisons of cell populations in high-dimensional cytometry data. Methods, 2018, 132, 66-75.	3.8	36
10	Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine. Frontiers in Immunology, 2018, 9, 870.	4.8	7
11	Mass Cytometry Analysis Reveals the Landscape and Dynamics of CD32a+ CD4+ T Cells From Early HIV Infection to Effective cART. Frontiers in Immunology, 2018, 9, 1217.	4.8	22
12	SPADEVizR: an R package for visualization, analysis and integration of SPADE results. Bioinformatics, 2017, 33, 779-781.	4.1	53
13	In depth comparative phenotyping of blood innate myeloid leukocytes from healthy humans and macaques using mass cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 969-982.	1.5	29
14	Identification of Vaccine-Altered Circulating B Cell Phenotypes Using Mass Cytometry and a Two-Step Clustering Analysis. Journal of Immunology, 2016, 196, 4814-4831.	0.8	28
15	Endogenous TRIM5Î± Function Is Regulated by SUMOylation and Nuclear Sequestration for Efficient Innate Sensing in Dendritic Cells. Cell Reports, 2016, 14, 355-369.	6.4	31
16	In vivo imaging in NHP models of malaria: Challenges, progress and outlooks. Parasitology International, 2014, 63, 206-215.	1.3	18
17	A Nonintegrative Lentiviral Vector-Based Vaccine Provides Long-Term Sterile Protection against Malaria. PLoS ONE, 2012, 7, e48644.	2.5	28
18	Lentiviral Vector-Based Prime/Boost Vaccination against AIDS: Pilot Study Shows Protection against Simian Immunodeficiency Virus SIVmac251 Challenge in Macaques. Journal of Virology, 2009, 83, 10963-10974.	3.4	52

#	Article	IF	Citations
19	Lentiviral Vectors Encoding HIV-1 Polyepitopes Induce Broad CTL Responses In Vivo. Molecular Therapy, 2007, 15, 1203-1210.	8.2	57
20	A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. Veterinary Immunology and Immunopathology, 2005, 104, 273-280.	1.2	18
21	Plasmacytoid Dendritic Cells: Linking Innate and Adaptive Immunity. Journal of Virology, 2005, 79, 17-27.	3.4	322
22	Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor- viral RNA interactions. Journal of Clinical Investigation, 2005, 115, 3265-3275.	8.2	573
23	Human Immunodeficiency Virus Type 1 Activates Plasmacytoid Dendritic Cells and Concomitantly Induces the Bystander Maturation of Myeloid Dendritic Cells. Journal of Virology, 2004, 78, 5223-5232.	3.4	305
24	Successful Induction of Protective Antibody Responses againstHaemophilus influenzaeType b and Diphtheria after Transcutaneous Immunization with the Glycoconjugate Polyribosyl Ribitol Phosphateâ€“Crossâ€Reacting Material197Vaccine. Journal of Infectious Diseases, 2004, 190, 1177-1182.	4.0	24
25	DC-virus interplay: a double edged sword. Seminars in Immunology, 2004, 16, 147-161.	5.6	50
26	Modulation of immune responses with transcutaneously deliverable adjuvants. Vaccine, 2004, 22, 2385-2390.	3.8	27
27	Danger signals: a time and space continuum. Trends in Molecular Medicine, 2004, 10, 251-257.	6.7	111
28	Type I interferons promote cross-priming: more functions for old cytokines. Nature Immunology, 2003, 4, 939-941.	14.5	51
29	Transcutaneous Immunization with Tetanus Toxoid and Mutants ofEscherichia coliHeatâ€Labile Enterotoxin as Adjuvants Elicits Strong Protective Antibody Responses. Journal of Infectious Diseases, 2003, 188, 753-758.	4.0	54
30	A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91â€“108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. Molecular Immunology, 2002, 39, 323-331.	2.2	32
31	Applying peptide antigens onto bare skin: induction of humoral and cellular immune responses and potential for vaccination. Journal of Controlled Release, 2002, 85, 27-34.	9.9	20
32	Immunization onto bare skin with synthetic peptides: immunomodulation with a CpGâ€containing oligodeoxynucleotide and effective priming of influenza virusâ€specific CD4⁺ T cells. Immunology, 2002, 105, 204-212.	4.4	54
33	The bare skin and the nose as non-invasive routes for administering peptide vaccines. Vaccine, 2001, 19, 2708-2715.	3.8	32